Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis Madrid, Spain - June 26, 2020: Highl
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control | Journal for ImmunoTherapy of Cancer
Una nueva combinación de inmunoterapia permite erradicar lesiones tumorales en modelos animales
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine
Highlight Therapeutics announces follow-up results from Phase 2b study of BO -112 + anti-PD1 in confirmed anti-PD1 progressor mel
Highlight Therapeutics present developments for lead drug candidate BO-112 in patients with melanoma
Highlight Therapeutics y Pivotal trabajan conjuntamente en el tratamiento del melanoma y lanzan un ensayo clínico fase IIa para determinar la seguridad y eficacia de BO-112
Classes — Highlight Therapeutics
Classes — Highlight Therapeutics
La valenciana Highlight Therapeutics cierra una ronda de 22,6 millones para terapias oncológicas - Fundación Conexus
Highlight Therapeutics
Highlight Therapeutics looks to boost the power and reach of immuno-oncology drugs
Our Instructors — Highlight Therapeutics
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety - Pivotal
Highlight Therapeutics & Pivotal advance into a phase IIa to examine gastro-intestinal cancer therapy - Pivotal
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO- 112 + STING agonist published
El Incliva participa en un ensayo Fase II de la primera inmunoterapia española frente a las metástasis de más difíciles
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine
Classes — Highlight Therapeutics
Our Instructors — Highlight Therapeutics
Our Instructors — Highlight Therapeutics
Classes — Highlight Therapeutics
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine
Classes — Highlight Therapeutics
